Skip to main content
. 2022 Jun 23;14(13):3094. doi: 10.3390/cancers14133094

Table 4.

Clinical studies with combined PD-1 and CTLA-4 inhibitors in metastatic UM patients.

Study Type Therapy Patients Enrolled ORR DCR mPFS mOS Reference
Single arm, phase II Nivolumab and ipilimumab 52 11.5% 63.5%
(1CR,5PR,27SD)
3 months 12.7 months [75]
NCT02626962
Single arm, phase II Nivolumab and ipilimumab 35
(33 evaluable)
18% 51.5%
(1CR,5PR,11SD)
5.5 months 19.1 months [72]
Retrospective PD-1 inhibitor and ipilimumab 15
(12 evaluable)
16.7% 33.3%
(2PR,2SD)
2.8 months NR [70]
Multicenter, retrospective Nivolumab/pembrolizumab and ipilimumab 64 15.6% 37.5%
(2CR,8PR,14SD)
3 months 16.1 months [76]
Multicenter, retrospective Ipilimumab and nivolumab 89 11.6% 36%
(1CR,9PR,21SD)
2.7 months 15 months [77]
Retrospective population-based Ipilimumab and nivolumab 19 21.1% 31.6%
(4PR,2SD)
3.7 months 18.9 months [54]
Single center,
retrospective
Ipilimumab and nivolumab in combination with TACE 8 25% 75%
(2PR,4SD)
NR 14 months [78]
Multicenter, retrospective PD-1 inhibitor and CTLA-4 inhibitor (dual ICI) Cohort A (liver metastases only)
34
8.7% 35.3%
(3PR,9SD)
NR NR [56]
Cohort B (several metastatic sites)
60
16.7% 43.3%
(10PR,16SD)
NR NR
Total 94 13.8% 40.4%
(13PR,25SD)
NR NR

ORR, overall response rate; DCR, disease control rate; mPFS, median progression-free survival; mOS, median overall survival; NR, not reported; CR, complete response; PR, partial response; SD, stable disease; TACE, transarterial chemoembolization; ICI, immune checkpoint inhibitor.